Loading, please wait...
|
LINK TO EVALUATION >> (opened after session) |
PARKING REQUEST FORM » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Tuesday, November 15, 2022
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
|
|
Link to Teams Meeting
|
||||
|
Links to Handouts
|
||||
|
SESSION 1
1:00 – 1:45
|
Abigail Kosharek, PharmD
Clostridium Difficile Prophylaxis after Allogeneic Hematopoietic Cell Transplantation
|
Emily Stephens, PharmD
Vitamin C in Sepsis
|
Jacob DeSalvo, PharmD
Regulate Your Appetite - A GLP-1 Agonist for Weight Loss
|
Katie Krausz, PharmD
Management of Acute Agitation in Pediatric Patients
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 2
1:55 – 2:40
|
Jesse Smith, PharmD
Management of Patients Undergoing Hematopoietic Stem Cell Transplant after Solid Organ Transplant
|
Eric Johnston, PharmD
Optimal Timing of Corticosteroids in Septic Shock
|
Naomi Bailey, PharmD
Buprenorphine Microinduction for Chronic Pain
|
Tessa Johanning, PharmD
Exploring the Role of Potassium Binders to Manage Hyperkalemia
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 3
2:50 – 3:35
|
Lauren Spreen, PharmD
Use of Post-Transplant Cyclophosphamide in Matched Unrelated Donor Allogeneic Transplant
|
Lauren Johnston, PharmD
Fluid Balance in Septic Shock Following Initial Resuscitation
|
Danny Tran, PharmD
Venous Thromboembolism: Use of Direct Oral Anticoagulants in Obesity
|
Jordan Welch
Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Post-PCI
|
Please join us for the second Resident Seminar session of the 2022-2023 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in classrooms in the Academic & Research Building (ARB) on the third floor (see classroom numbers above), as well as virtually (see Teams links above).
Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned for this Resident Seminar is 2.25 contact hours. Participants must complete an evaluation (see link above) to receive credit.
Click here for a printable copy of the schedule
REGISTRATION: To register for the LIVE Resident Seminar presentations, click here>>>. There is no need to register for the virtual presentations. Please use the links within the table above to connect to the VIRTUAL presentations. Special note, this event has multiple concurrent sessions.
Due to a limited number of live available classroom spaces, a maximum of 30 people are allowed per classroom. Virtual attendance is limitless.
Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, November 11, 2022 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Participants attending the LIVE (on-campus) sessions will be provided paper copies of handouts within the classrooms. Virtual attendees can access the handouts in the conversation feature within Teams. Copies of PowerPoint slides are not provided.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. The evaluation link will open immediately following Resident Seminar. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. The evaluation link will open immediately following Resident Seminar. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy in St. Louis is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close November 22, 2022 at 11:59 PM (CST).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Learn more! Click the + symbol below to expand.
Date: Nov 15, 2022 01:00 AM - 03:35 AM
Fee
$0.00
CE Hours
9.00
Activity Type
- Knowledge
The presentation will begin by describing the different aspects of C. difficile infection including, risk factors and treatment. Then will discuss alloHCT and the risk factors associated with alloHCT that may lead to C. difficile infections. After we will discuss the many complications associated with C. difficile infection in alloHCT, including graft-versus-host disease. Next, talk about different potential prevention strategies. Lastly, review relevant literature surrounding C. difficile prophylaxis in alloHCT.
Objectives
- Describe risk factors and complications associated with Clostridioides difficile infection after allogeneic hematopoietic cell transplant.
- Discuss current literature surrounding prophylaxis for Clostridioides difficile in patients who receive an allogeneic hematopoietic cell transplant
Speaker(s)/Author(s)
|
Abigail Kosharek, PharmD |
Activity Number
0033-0000-22-029-L01-P
Date:
11/15/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 304 and Virtually
Despite efforts for improvement in the treatment of sepsis, mortality rates remain high. The use of vitamin C in sepsis is thought to be beneficial due to the anti-inflammatory properties, effects on the endothelial barrier, and facilitation of the release of various endogenous substances. The 2021 Surviving Sepsis Guidelines recommend against the use of vitamin C in sepsis and septic shock. Since these guidelines were published there have been new studies in which specific sepsis subgroups were assessed as well as different doses and durations of vitamin C, and different combinations of vitamin C, hydrocortisone, and thiamine. This seminar presentation will discuss all pertinent existing data surrounding vitamin C in sepsis.
Objectives
- Describe the mechanism of action of vitamin C as it relates to the pathophysiology of sepsis
- Summarize the current literature available regarding vitamin C in sepsis
- Select appropriate guideline recommendations for the treatment of vitamin C in sepsis
Speaker(s)/Author(s)
|
Emily Stephens, PharmD |
Activity Number
0033-0000-22-026-L01-P
Date:
11/15/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This presentation will educate pharmacists on the data behind the new FDA approval of semaglutide 2.4mg weekly for weight loss, primarily focusing on the STEP (Semaglutide Treatment Effect in People with obesity) trials. It will also spend time evaluating the data for a new drug with a unique mechanism of action that will likely soon be FDA approved for weight loss, tirzepatide - a new GIP/GLP-1 agonist.
Objectives
- Identify health problems commonly associated with overweight and obese individuals
- Identify the place in therapy of GLP-1 agonists for the weight management of adults
- Identify the most common types of side effects associated with GLP-1 agonists used for weight loss
Speaker(s)/Author(s)
|
Jacob DeSalvo, PharmD |
Activity Number
0033-0000-22-030-L01-P
Date:
11/15/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 354 and Virtually
This presentation will first discuss the pathophysiology of acute agitation with underlying psychiatric diagnoses. Based on the current guidance documents, it will then discuss common medications, the mechanisms of action and how they best fit into treatment based on the psychiatric diagnosis. It will also discuss the situations to not use the medications and formulations of the medications. At the end of the presentation, the presenter will discuss her recommendations on when to use each medication based on the reason for presentation. The overall goal for the audience from this presentation is to be determine appropriate therapy for pediatric acute agitation based on underlying diagnosis, formulations and contraindications.
Objectives
- Identify the neurotransmitters involved in acute agitation
- Select appropriate therapy for a pediatric patient with acute agitation
Speaker(s)/Author(s)
|
Katie Krausz, PharmD |
Activity Number
0033-0000-22-036-L01-P
Date:
11/15/22
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Although rare, patients who have previously undergone a solid organ transplant can develop malignancy that requires hematopoetic stem cell transplant . This seminar will introduce the audience to the background on how malignancy develops in solid organ transplant, considerations for immunosuppression after hematopoetic stem cell transplant, and complications that can arise post-transplant.
Objectives
- Describe the risk of malignancy in solid organ transplant
- Identify immunosuppression strategies post-hematopoietic stem cell transplant in patients with a previous solid organ transplant
- Discuss the prevention and management of complications post-hematopoietic stem cell transplant
Speaker(s)/Author(s)
|
Jesse Smith, PharmD |
Activity Number
0033-0000-22-038-L01-P
Date:
11/15/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304 and Virtually
The essentials of septic shock management include antimicrobial therapy, fluid resuscitation, and vasopressors. Corticosteroids are suggested by the 2021 Surviving Sepsis guidelines for patients who have been on vasopressors for at least four hours and are receiving a dose of at least norepinephrine 0.25mcg/kg/min. Randomized controlled trials support corticosteroids as a therapy associated with the benefit of reducing the duration of vasopressor use in septic shock: a profound benefit given the adverse effects associated with vasopressor administration.
A critical shortcoming of the data surrounding corticosteroids in septic shock is when the optimal time to initiate corticosteroids is. Recent retrospective studies inform how corticosteroid timing is a key element in maximizing vasopressor reductions in septic shock. This presentation will inform on the practice of early initiation of corticosteroids in septic shock with proposals of what time cutpoints optimize this practice.
Objectives
- Explain potential mechanisms of action by which corticosteroids may exert their therapeutic effect in septic shock
- Identify the appropriate corticosteroid drug, dose, route, and frequency if indicated for septic shock
- Select the appropriate time to initiate corticosteroids in septic shock based on time from shock onset and concurrent therapies in use
Speaker(s)/Author(s)
|
Eric Johnston, PharmD |
Activity Number
0033-0000-22-031-L01-P
Date:
11/15/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305 and Virtually
This presentation will provide a general overview of buprenorphine as an analgesic, highlighting the pharmacokinetics and unique properties of this drug. It will discuss typical strategies for transition to buprenorphine including opioid tapers and conventional buprenorphine initiation in patients with opioid use disorder. Available data regarding microinduction with buprenorphine will be reviewed, This will include data on the initial case series involving the Bernese method and then focusing on data specifically in those with chronic pain. The presentation will conclude with a discussion surrounding clinical application of this information.
Objectives
- List proposed benefits of buprenorphine as compared to a full mu agonist
- Describe the theorized mechanism behind microinduction with buprenorphine
- Summarize available data on microinduction strategies in chronic pain
Speaker(s)/Author(s)
|
Naomi Bailey, PharmD |
Activity Number
0033-0000-22-034-L01-P
Date:
11/15/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354 and Virtually
Hyperkalemia can have serious clinical consequences, including adverse cardiovascular outcomes and death, and often limits the use of renin-angiotensin-aldosterone system inhibitors (RAASI). Approximately 47% of patients prescribed the maximum recommended doses of RAASI are down-titrated to suboptimal doses or discontinued if their serum potassium rises to 5.5 mEq/L or greater. RAASI are known to reduce chronic kidney disease progression and reduce morbidity and mortality in patients with heart failure. There is accumulating evidence suggesting discontinuation and dose reduction of these medications is associated with increased mortality risk. There is expanding literature assessing safety and efficacy of potassium binders in patients with heart failure and chronic kidney disease to allow for continuation of medications shown to reduce morbidity and mortality when clinically indicated. Novel potassium binders may be the key to reducing hyperkalemia and continuing these patients on guideline directed medical therapy; however, current guideline recommendations are lacking in this area.
Objectives
- Identify patients at risk for developing hyperkalemia
- Differentiate adverse effects associated with agents used for management of hyperkalemia
- Discuss available literature representing the efficacy and safety associated with the use of potassium binders in heart failure and/or chronic kidney disease
- Select patients who may benefit from potassium binder therapy
Speaker(s)/Author(s)
|
Tessa Johanning, PharmD |
Activity Number
0033-0000-22-037-L01-P
Date:
11/15/22
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355 and Virtual
The safety and efficacy of post-transplant cyclophosphamide on graft rejection and graft versus host disease (GVHD) has been demonstrated in the haploidentical allogeneic stem cell transplant population. It's use is more recently being studied in the matched unrelated donor (MUD) allogeneic stem cell transplant population; however, there is a current gap in knowledge on whether post-transplant cyclophosphamide is superior to historical GVHD prophylaxis regimens such as methotrexate and a calcineurin. This continuing education activity will briefly describe the data surrounding some of the historical GVHD prophylaxis regimens and then review some of the key literature on post-transplant cyclophosphamide in the MUD population. The goal for the audience is to understand why GVHD prophylaxis is important in allogeneic stem cell transplantation and evaluate the data supporting post-transplant cyclophosphamide in the MUD population.
Objectives
- Describe the incidence of and risk factors for GVHD in allogeneic stem cell transplant recipients
- Discuss the mechanism of PTCy in GVHD prevention
- Evaluate the literature of PTCy in combination with immunosuppressant agents for MUD allogeneic SCTs
Speaker(s)/Author(s)
|
Lauren Spreen, PharmD |
Activity Number
0033-0000-22-035-L01-P
Date:
11/15/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 304 and Virtually
The 2021 Surviving Sepsis Guidelines provide clear recommendations regarding initial fluid resuscitation in patients with septic shock in that 30mL/kg of crystalloid fluid should be given within the first 3 hours to support tissue perfusion. Beyond this, the guidelines offer suggestions for how fluid status should be monitored, but lack direction for how to proceed with continuing fluid use after initial resuscitation. This paucity of information represents a weakness in the care of patients with septic shock that pharmacists are well-positioned to address in practice. Therefore, this seminar presentation will educate pharmacists on how excess fluid balance contributes to increased mortality, how to effectively monitor fluid balance, and provide an in-depth analysis of recent literature that informs patient outcomes with various fluid administration strategies after initial resuscitation. By effectively combining these elements, pharmacists will be able to provide direction in the care of patients with septic shock regarding their fluid administration choices.
Objectives
- Identify harms of fluid overload in patients with septic shock
- Describe appropriate measures of fluid responsiveness in patients with septic shock
- Describe current literature regarding fluid administration following initial resuscitation in septic shock
Speaker(s)/Author(s)
|
Lauren Johnston, PharmD |
Activity Number
0033-0000-22-033-L01-P
Date:
11/15/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 305 and Virtually
According to the CDC in 2016, more than 1.9 billion adults were overweight with 650 million who were obese (BMI > 30 kg/m2). This patient population is at an increased risk for various diseases, including VTE. While current guidelines recommend DOAC therapies, obese patients were not well-represented in the trials that support these recommendations. This presentation will review the pathophysiology, risk factors, and treatment for the general population, while focusing on the prothrombotic pathways and the impact of obesity on the kinetics of DOACs. In addition, previous and current literature will be critically analyzed to propose an algorithm for VTE treatment in obesity.
Objectives
- Identify risk factors for developing venous thromboembolism
- Discuss current literature on the use of direct oral anticoagulants as VTE treatment in obes
Speaker(s)/Author(s)
|
Danny Tran, PharmD |
Activity Number
0033-0000-22-032-L01-P
Date:
11/15/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 354 and Virtually
The agent selection as well as duration of triple antiplatelet therapy will be discussed in this seminar. There will be a background review of atrial fibrillation, PCI, and the combination of the two. There will be a current literature review of 7 RCTs and 1 meta-analysis, as well as American and European clinical practice guidelines on the subject. The focus of the presentation is to educate the audience about anticoagulation and P2Y12 inhibitor selection, as well as how to make an informed decision about triple therapy duration in regard to the patient's stroke and bleeding risk. Questions incorporating the material discussed will be used as knowledge checkpoints throughout the presentation.
Objectives
- Define triple antithrombotic oral therapy
- Identify safety and efficacy parameters associated with triple antithrombotic therapy
- Develop a treatment plan based on guideline and primary literature recommendations in patients with AF post-PCI
Speaker(s)/Author(s)
|
Jordan Welch, PharmD |
Activity Number
0033-0000-22-028-L01-P
Date:
11/15/22
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 355 and Virtually
